📰 Clinically Utilized News
Page 2 - Clinically Utilized News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Clinically Utilized. Real-time updates on events, politics, business and more.
November 3, 2022
03.11.2022 - Media Release Copenhagen, Denmark, November 3, 2022 Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational epcoritamab (DuoBody-CD3xCD20) in a variety of treatment settings and hematologic ...
November 3, 2022
Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational epcoritamab (DuoBody-CD3xCD20) in a variety of treatment settings and hematologic malignancies
October 28, 2022
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) for...
October 28, 2022
Genmab has Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for epcoritamab European Medicines Agency (EMA) has validated Marketing Authorization Application
June 30, 2022
Company Announcement COPENHAGEN, Denmark; June 30, 2022 – Genmab A/S (Nasdaq: GMAB) today announced its intent to submit a biologics license application...
June 11, 2022
Epcoritamab demonstrated clinically meaningful efficacy in challenging to treat, highly refractory LBCL patients, including patients previously treated with chimeric antigen receptor (CAR) T-cell therapyTotal patient population achieved overall response rate (ORR) of 63 percent and complete response (CR) of 39 perce...
June 11, 2022
Epcoritamab demonstrated clinically meaningful efficacy in challenging to treat, highly refractory LBCL patients, including patients previously treated with chimeric antigen receptor (CAR) T-cell
May 27, 2022
Press release content from Business Wire. The AP news staff was not involved in its creation.
May 26, 2022
(2022-05-26 | NDAQ:GMAB) Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2022
Multiple epcoritamab (DuoBody-CD3xCD20) poster presentations highlighting data in a variety of treatment settings and hematologic malignancies Oral presentation of tisotumab vedotin first-line